Berchuck A - Search Results

1

Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins.

Phung MT, Lee AW, Wu AH, Berchuck A, Cho KR, Cramer DW, Doherty JA, Goodman MT, Hanley GE, Harris HR, McLean K, Modugno F, Moysich KB, Mukherjee B, Schildkraut JM, Terry KL, Titus LJ, Jordan SJ, Webb PM, Pike MC, Pearce CL; Ovarian Cancer Association Consortium; Australian Ovarian Cancer Study Group and the Ovarian Cancer Association Consortium; Ovarian Cancer Association Consortium. Phung MT, et al. Among authors: berchuck a. Cancer Epidemiol Biomarkers Prev. 2021 May;30(5):927-935. doi: 10.1158/1055-9965.EPI-20-1355. Epub 2021 Feb 22. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 33619020 Free PMC article.

2

Improved palliation of cerebral metastases in epithelial ovarian cancer using a combined modality approach including radiation therapy, chemotherapy, and surgery.

Rodriguez GC, Soper JT, Berchuck A, Oleson J, Dodge R, Montana G, Clarke-Pearson DL. Rodriguez GC, et al. Among authors: berchuck a. J Clin Oncol. 1992 Oct;10(10):1553-60. doi: 10.1200/JCO.1992.10.10.1553. J Clin Oncol. 1992. PMID: 1383433

3

Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer.

Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC Jr. Olt G, et al. Among authors: berchuck a. Cancer. 1992 Oct 15;70(8):2137-42. doi: 10.1002/1097-0142(19921015)70:8<2137::aid-cncr2820700821>3.0.co;2-w. Cancer. 1992. PMID: 1394043

4

Loss of heterozygosity on chromosome 17q11-21 in cancers of women who have both breast and ovarian cancer.

Schildkraut JM, Collins NK, Dent GA, Tucker JA, Barrett JC, Berchuck A, Boyd J. Schildkraut JM, et al. Among authors: berchuck a. Am J Obstet Gynecol. 1995 Mar;172(3):908-13. doi: 10.1016/0002-9378(95)90020-9. Am J Obstet Gynecol. 1995. PMID: 7892884

5

Role of BRCA1 mutation screening in the management of familial ovarian cancer.

Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR. Berchuck A, et al. Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):738-46. doi: 10.1053/ob.1996.v175.a74288. Am J Obstet Gynecol. 1996. PMID: 8828444 Review.

6

Relationship between lifetime ovulatory cycles and overexpression of mutant p53 in epithelial ovarian cancer.

Schildkraut JM, Bastos E, Berchuck A. Schildkraut JM, et al. Among authors: berchuck a. J Natl Cancer Inst. 1997 Jul 2;89(13):932-8. doi: 10.1093/jnci/89.13.932. J Natl Cancer Inst. 1997. PMID: 9214672

7

Oral contraceptive pills. Prevention of ovarian cancer and other benefits.

Berchuck A, Schildkraut J. Berchuck A, et al. N C Med J. 1997 Nov-Dec;58(6):404-7; discussion 408. N C Med J. 1997. PMID: 9392951 Review.

8

Managing hereditary ovarian cancer risk.

Berchuck A, Schildkraut JM, Marks JR, Futreal PA. Berchuck A, et al. Cancer. 1999 Dec 1;86(11 Suppl):2517-24. doi: 10.1002/(sici)1097-0142(19991201)86:11+<2517::aid-cncr8>3.0.co;2-b. Cancer. 1999. PMID: 10630177 Review.

9

Prognostic factors in early-onset epithelial ovarian cancer: a population-based study.

Schildkraut JM, Halabi S, Bastos E, Marchbanks PA, McDonald JA, Berchuck A. Schildkraut JM, et al. Among authors: berchuck a. Obstet Gynecol. 2000 Jan;95(1):119-27. doi: 10.1016/s0029-7844(99)00535-9. Obstet Gynecol. 2000. PMID: 10636514

10

Types and duration of symptoms prior to diagnosis of invasive or borderline ovarian tumor.

Vine MF, Ness RB, Calingaert B, Schildkraut JM, Berchuck A. Vine MF, et al. Among authors: berchuck a. Gynecol Oncol. 2001 Dec;83(3):466-71. doi: 10.1006/gyno.2001.6411. Gynecol Oncol. 2001. PMID: 11733956

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

628 results

Search Page